EXACT Sciences Corporation (NASDAQ: EXAS) announced today that it is scheduled to present at the Leerink Swann Future of Molecular Diagnostics Roundtable Conference on Thursday, April 3, 2008. The presentation will be webcast live and may be accessed by visiting the Investors’ section of the Company’s website, www.exactsciences.com.
Jeffrey R. Luber, EXACT Sciences’ President and Chief Executive Officer, is scheduled to deliver the presentation at 1:40 p.m. ET at the Sofitel Hotel in New York City. An archived version of the webcast will be available for 30 days.
In addition, pursuant to the rules of the NASDAQ Global Market, EXACT announced that, based on its available cash, it received a going concern explanatory paragraph in the unqualified audit opinion included in its Annual Report on Form 10-K which was recently filed with the Securities and Exchange Commission. This announcement does not represent any change to the Company’s Annual Report on Form 10-K or the financial statements included therein. EXACT previously announced that it has retained Leerink Swann LLC to evaluate and advise its Board of Directors regarding strategic alternatives for the business.
About EXACT Sciences Corporation
EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings® (LabCorp®) for a stool-based DNA (sDNA) assay developed by LabCorp for colorectal cancer screening in the average-risk population and marketed by LabCorp under the name PreGen-Plus™. EXACT Sciences’ sDNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer (a group comprised of representatives from the American College of Gastroenterology, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy), and the American College of Radiology. EXACT Sciences believes its genomics-based technologies will help enable earlier detection of colorectal cancer so that more people can be effectively treated. EXACT Sciences is based in Marlborough, Mass. PreGen-Plus, the non-invasive colorectal cancer screening testing service offered by LabCorp, has not been approved or cleared by the U.S. Food & Drug Administration.
Certain statements made in this press release that are not based on historical information are express or implied forward-looking statements relating to, among other things, EXACT Sciences' expectations concerning, among other things, the timing and content of corporate presentations. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond EXACT Sciences' control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. EXACT Sciences undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by EXACT Sciences, see the disclosure contained in EXACT Sciences' public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.
Contacts:
Jeffrey Luber, 508-683-1275
President
and Chief Executive Officer
